← Back to Search

Behavioral Intervention

ECA-HPV App for Human Papillomavirus

N/A

Waitlist Available

Led By Michael Paasche-Orlow, MD, MPH

Research Sponsored by Tufts Medical Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be younger than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 16 months

Awards & highlights

No Placebo-Only Group

Summary

This trial aims to evaluate how well a program called ECA-HPV works in increasing HPV vaccination rates and satisfaction over a 16-month period. The study will also compare the effectiveness of clinic notification

Who is the study for?

This trial is for individuals dealing with warts or human papillomavirus (HPV). The study aims to include a diverse group of participants, but specific eligibility criteria are not provided in the information given.

What is being tested?

The trial is testing an app called ECA-HPV in different configurations: with clinic notifications and adolescent functions either enabled or disabled. It compares these against usual care over 16 months to see if they increase HPV vaccine uptake and satisfaction.

What are the potential side effects?

Since this trial involves a digital application rather than medication, traditional side effects are not applicable. However, there may be privacy concerns or potential stress related to using the app.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 16 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~16 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 16 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

HPV vaccination series completion comparing the control group to the intervention groups

HPV vaccination series completion comparing the intervention groups

Secondary study objectives

Clinic Notification Feature Satisfaction

ECA-HPV App Satisfaction

General Vaccine Attitudes

+2 more

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

5Treatment groups

Experimental Treatment

Active Control

Group I: ECA-HPV App with Clinic Notification and Adolescent Functions EnabledExperimental Treatment1 Intervention

Participants will receive the full ECA-HPV (Embodied Conversational Agent adapted for this project) system on their smartphone app, which includes both the clinic notification and adolescent functions enabled. With the clinic notification function enabled, parent/guardian participants can communicate their concerns, questions, and logistical barriers to the clinic staff. Adolescent participants receive the adolescent version of the ECA-HPV app, which includes age-appropriate education and adolescent-focused engagement features, like games. An internet-based measure, REDCap, will be used for parent/guardian and adolescent participants to complete surveys at baseline, after the index well child visit, and after the second well child visit.

Group II: ECA-HPV App with Clinic Notification and Adolescent Functions DisabledExperimental Treatment1 Intervention

The ECA-HPV (Embodied Conversational Agent adapted for this project) system comprises of a smartphone-based ECA parent/guardian interface, where the parent/guardian participants can receive HPV vaccine promotion and counseling from an interactive agent. The clinic notification feature is disabled on the app. Adolescent participants do not receive the adolescent version of the ECA-HPV app. An internet-based measure, REDCap, will be used for parent/guardian and adolescent participants to complete surveys at baseline, after the index well child visit, and after the second well child visit.

Group III: ECA-HPV App with Clinic Notification Function EnabledExperimental Treatment1 Intervention

The ECA-HPV (Embodied Conversational Agent adapted for this project) system comprises of a smartphone-based ECA parent/guardian interface, where the parent/guardian participants can receive HPV vaccine promotion and counseling from an interactive agent. With the clinic notification function enabled, parent/guardian participants can communicate their concerns, questions, and logistical barriers to the clinic staff. Adolescent participants do not receive the adolescent version of the ECA-HPV app. An internet-based measure, REDCap, will be used for parent/guardian and adolescent participants to complete surveys at baseline, after the index well child visit, and after the second well child visit.

Group IV: ECA-HPV App with Adolescent Function EnabledExperimental Treatment1 Intervention

The ECA-HPV (Embodied Conversational Agent adapted for this project) system comprises of a smartphone-based ECA parent/guardian interface, where the parent/guardian participants can receive HPV vaccine promotion and counseling from an interactive agent. Adolescent participants receive the adolescent version of the ECA-HPV app, which includes age-appropriate education and adolescent-focused engagement features, like games. The clinic notification feature is disabled on both the parent/guardian and adolescent apps. An internet-based measure, REDCap, will be used for parent/guardian and adolescent participants to complete surveys at baseline, after the index well child visit, and after the second well child visit.

Group V: Usual CareActive Control1 Intervention

An internet-based measure, REDCap, will be used for parent/guardian and adolescent participants to complete surveys at baseline, after the index well child visit, and after the second well child visit. Both parent/guardian and adolescent participants do not have access to the ECA-HPV app. Adolescent participants will receive usual standard of care.

Do I qualify?Apply below to find out